🔗 Share this article

Given that the US undertakes unprecedented changes to its immunization recommendations, a particular individual has emerged unexpectedly: Tracy Beth Høeg, a Danish American sports physician and epidemiologist who first made her name by expressing skepticism about COVID-19 shots during the global health crisis and has zeroed in on potential fatalities following Covid immunization in her recent tenure at the FDA.

Planned Shifts to Childhood Immunization Program

Agency leaders had intended to announce radical changes to the pediatric immunization program earlier this month, bringing the US with the Danish vaccine program, according to reports – a major change that would put the US out of alignment with much of the international standard with little proof for improved outcomes. This reveal has been delayed until the coming year.

Rather than Vinay Prasad, Dr. Høeg is scheduled to speak at the gathering. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the center this year.

A New Direction at the FDA

This interim role could signify a closer partnership between the pharmaceutical and vaccine divisions as Dr. Høeg and Prasad strengthen their influence at the FDA – and it points to a renewed priority upon rolling back long-standing immunizations at the FDA.

Dr. Høeg has frequently advocated for halting specific pediatric vaccine recommendations in the US in order to be more similar to the Danish model, a country with comprehensive healthcare and a population about the size of the state of Wisconsin.

To date comments, she has continued to focus on vaccines – traditionally the domain of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to medication approval.

Concerns Over Expertise

Høeg has little discernible background in medication creation, regulation or leadership, which has been customary for past heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the commissioner and the vaccine center since March.

“She doesn’t seem to have the necessary background” for overseeing the CDER, said Jonathan Howard. “She lacks experience running a clinical trial. She lacks experience in managing a sizeable institution. She lacks background in industry regulation.”

Previous commissioners of CBER would “be deeply familiar with regulatory frameworks and the underlying principles of drug development”, said a former acting FDA commissioner. “Clearly, she has not acquired the sort of resume that previous people who ran the center have had.”

This division has an enormous range of responsibilities at the agency, Woodcock pointed out.

“The public just zeroes in on the new drug program, but the generic drug division clears thousands of generic drugs. There’s a biosimilars division, non-prescription drug unit and so forth, and all of those must be looked after,” Dr. Woodcock said. “The responsibility you overlook, that is precisely what that I always told people is going to bite you.”

Additionally, a significant management component to the position, which oversees more than 5,000 employees. “It is a massive leadership role, if you execute it properly,” she said.

Response and Disputed Policies

In response to concerns about Høeg’s fitness for the role and whether this appointment signifies more teamwork among regulatory chiefs on immunizations, a representative stated that the “concerns rely on flawed assumptions”.

“Her resume is consistent with the duties of her role,” the official stated, citing the period Dr. Høeg spent advising the FDA commissioner on “medication safety and approval science, including predictive safety algorithms and immunization monitoring”.

In her interim role, Høeg assumes responsibility for the commissioner’s new expedited review system, a contentious rapid medication authorization process that allegedly troubled her predecessors. “How are these therapies being selected for this fast-track system? Who is making the choices?” Dr. Howard said. “There’s a lot of lack of transparency going on at the agency right now.”

Overall, he remarked, “the agency seems to be moving towards more relaxed regulations of pharmaceuticals, aside from vaccines.”

Public Past Work on Immunizations

With immunizations, Dr. Høeg has a more documented, if concerning, history, critics observe. She authored a study using unconfirmed public submissions to determine the rate of heart inflammation after COVID-19 immunization. She advised the Florida top health official Joseph Ladapo, who allegedly have modified findings to imply Covid vaccinations are riskier than they are.

Among her “policy goals” for the incoming federal leadership encompassed changing guidelines for novel immunizations and halting “optional” vaccines, she stated following the vote on a podcast. At the agency, Høeg has allegedly proposed preventing teenage boys from receiving COVID-19 vaccines.

“She’s an complete ideologue who begins with her preconceived notions and works backwards to retrofit the evidence in a extremely deceptive, fraudulent way,” Dr. Howard stated.

Taking Control and a “Campaign of Retribution”

Dr. Høeg aligned with other dissenters, {like|